Airfinity May Data Set

Source: Airfinity
Contact Airfinity: infectiousdiseases@airfinity.com
Contact IFPMA: info@ifpma.org

May 2023
COVID-19 treatment candidate pipeline

968 in preclinical development
898 in clinical development
41 Approved Tx
17 Approved in the U.S, U.K or E.U. (2 Fully Approved)
24 approved in other countries (only)
Of which, 7 WHO endorsed

- U.S./U.K./E.U. Approved:
  - Remdesivir (Full approval)
  - Baricitinib (Full approval)
  - Tocilizumab (EUA)
  - Sarilumab (EUA)
  - Anakinra (EUA)
  - Dexamethasone (EUA)
  - Hydrocortisone (EUA)
  - LY-CoV555 mono-therapy (EUA)
  - REGEN-COV (EUA)
  - CT-P59 (EUA)
  - Sotrovimab (EUA)
  - Evusheld (EUA)
  - Paxlovid (Nirmatrelvir with Ritonavir) (EUA)
  - LY-CoV1404 (EUA)
  - LY-CoV555 + LY-CoV016 combination (EUA)
  - Molnupiravir (EUA)
  - Ifx-1 (Vilobelimab) (EUA)

- Repurposed = candidate is approved for an alternate disease indication

© 2023 Airfinity
COVID-19 therapeutics collaboration deals

For total collaborations: 176 signed
158 for manufacturing and 18 for
distribution (176-18 = 158) 165 are
active, 148 for manufacturing and
17 for distribution

Of the total manufacturing
agreements signed - 158
148 are active and at least 10 are
inactive

Note: interruption of deals is
often not announced publicly,
therefore the number of
inactive deals may differ.

Collaborations include: Distribution and commercialisation partners, Voluntary Licensing
Agreements, Manufacturing partners, Medicines Patent Poll sublicensees

176 Total Collaborations
43 manufacturing licensing agreements were signed in the first year of the pandemic, tripling by June 2022

- 44 generic manufacturers signed MPP VLAs for Paxlovid (Nirmatrelvir; Ritonavir) – 38 parent companies and 6 of their subsidiaries – 3 parent companies have since withdrawn from the MPP bringing the total to 35 MPP sublicensees with an additional 6 of subsidiaries.
- 29 generic manufacturers signed MPP VLAs for Molnupiravir – 27 parent companies and 2 of their subsidiaries – 4 parent companies have since withdrawn from the MPP bringing the total to 23 MPP sublicensees with an additional 2 of subsidiaries.
- MSD* signed bilateral VLAs with 8 generic manufacturers for Molnupiravir
- Eli Lilly signed bilateral VLAs with 8 generic manufacturers for Baricitinib
- Gilead signed bilateral VLAs with 9 generic manufacturers for Remdesivir

*Known as Merck in the United States and Canada, and as MSD outside of the United States and Canada.

Manufacturing agreements are recorded when announced. Agreements can be amended/removed following company updates.

Cumulative Manufacturing Agreements

1 relevant agreement between Regeneron and Sanofi for the production of Sarilumab pre-dates 2020 (2007)

43 manufacturing deals were in place at the end of the first year of the pandemic, 1 of which has since been cancelled/interrupted

104 manufacturing deals were in place at the end of the second year of the pandemic, 8 of which have since been cancelled/interrupted

158 manufacturing deals were signed by the end of the second year of the pandemic, 10 of which have since been inactive

148 active – 10 inactive

Total 158 signed

Note: interruption of deals is often not announced publicly, therefore the number of inactive deals may differ.
43 manufacturing licensing agreements were signed in the first year of the pandemic, tripling by June 2022.
Existing voluntary licensing agreements map: location of licensees and sublicensees for Nirmatrelvir + Ritonavir, Molnupiravir and Remdesivir

78 VLAs in total:
- 9 Remdesivir
- 38 Paxlovid
- 31 Molnupiravir

72 out of 78 VLAs (92%) are with manufacturers based in developing countries
Overview of WHO recommended COVID-19 therapeutic approvals

Regulatory decisions on the 7 WHO recommended COVID-19 treatments worldwide

WHO Recommended COVID-19 Treatments:
- Remdesivir
- Nirmatrelvir + Ritonavir
- Molnupiravir
- Tocilizumab
- Sarilumab
- Baricitinib
- Dexamethasone

EMA – 4 candidates endorsed
EC – 3 candidates approved

© 2023 Airfinity
COVID-19 therapeutic collaborations: India

Total Collaborations* 68

Collaborations include: Distribution partners, VLAs, Manufacturing partners, MPP sublicensees

Source: 2023 Airfinity (Last Updated: March 2023)